Drug
Ostarine clinical trials
Also written Enobosarm, GTx-024 and Ostarine.
- studies test it
- 16
- open now
- 0
- in phase 3
- 3
- first study started
- 2007
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 12
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 1
GTx (11) · Veru Inc. (3) · City of Hope Medical Center (1) · Havah Therapeutics Pty Ltd (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ostarine is read from its arms, and is right about nine times in ten.
Testing it · 16
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossActive, not recruitingPhase 2Veru Inc.NCT07446998Written as Enobosarm
- Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtCompletedPhase 2Veru Inc.NCT06282458Written as Enobosarm
- Phase II Study of GTx024 in Women With Metastatic Breast CancerTerminatedPhase 2GTxNCT01616758Written as GTx-024 9mg
- Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary IncontinenceWithdrawnPhase 2GTxNCT03566290Written as GTx-024
- Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body MassWithdrawnPhase 2GTxNCT02746328Written as GTx-024 9 or 18 mg
- Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerCompletedPhase 2City of Hope Medical CenterNCT02971761Written as Enobosarm
- Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerTerminatedPhase 3Veru Inc.NCT04869943Written as Enobosarm
- Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary IncontinenceWithdrawnPhase 2GTxNCT03508648Written as GTx-024
- Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary IncontinenceCompletedPhase 2GTxNCT03241342Written as GTx 024
- GTx-024 as a Treatment for Stress Urinary Incontinence in WomenCompletedPhase 2GTxNCT02658448Written as GTx-024
- Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast CancerCompletedPhase 2GTxNCT02463032Written as GTx-024
- Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)TerminatedPhase 2GTxNCT02368691Written as GTx-024
- Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line PlatinumCompletedPhase 3GTxNCT01355497Written as GTx-024
- Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast DensityCompletedPhase 1Havah Therapeutics Pty LtdNCT03264651Written as enobosarm
- Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3GTxNCT01355484Written as GTx-024
- Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.CompletedPhase 2GTxNCT00467844Written as GTx-024
Codes
What other systems call ostarine · ClinicalTrials.gg INT005570
- MeSH (NLM) C547106ostarineOne source NLM
- UNII (FDA) O3571H3R8NENOBOSARMConfirmed FDA, NLM
- RxNorm 2168587One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547106 | ostarine | One source NLM |
| UNII (FDA) | O3571H3R8N | ENOBOSARM | Confirmed FDA, NLM |
| RxNorm | 2168587 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.